[go: up one dir, main page]

CO6190620A2 - Triazoles biciclicos como moduladores de la proteina cinasa - Google Patents

Triazoles biciclicos como moduladores de la proteina cinasa

Info

Publication number
CO6190620A2
CO6190620A2 CO09040677A CO09040677A CO6190620A2 CO 6190620 A2 CO6190620 A2 CO 6190620A2 CO 09040677 A CO09040677 A CO 09040677A CO 09040677 A CO09040677 A CO 09040677A CO 6190620 A2 CO6190620 A2 CO 6190620A2
Authority
CO
Colombia
Prior art keywords
substituted
unsubstituted
independently
heteroaryl
heterocycloalkyl
Prior art date
Application number
CO09040677A
Other languages
English (en)
Inventor
Pierre Bounaud
Christopher Ronald Smith
Original Assignee
Sgx Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sgx Pharmaceuticals Inc filed Critical Sgx Pharmaceuticals Inc
Publication of CO6190620A2 publication Critical patent/CO6190620A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

1.- Un compuesto de la fórmula I:o un enantiómero, diastereómero, raceomato o sal o solvato farmacéuticamente aceptable del mismo, CARACTERIZADO porque Q es independientemente hidrógeno. halógeno, alquilo sustituido o no sustituido, cicloalquilo sustituido o no sustituido, perfluoroalquilo, heteroalquilo sustituido o no sustituido, heterocicloalquilo sustituido o no sustituido, arilo sustituido o no sustituido, -O-arilo sustituido o no sustituido, arilalquilo sustituido o no sustituido, heteroarilo sustituido o no sustituido, -O- heteroarilo sustituido o no sustituido, o heteroarilalquilo sustituido o no sustituido, donde Q es opcional e independientemente sustituido con 1 a 3 R22; X es N o CR2;q es independientemente un número entero entre 0 y 2;R1 y R2 son cada uno opcional e independientemente hidrógeno, halógeno, nitro, ciano, hidroxilo, alquilo sustituido o no sustituido, perfluoroalquilo, -(CH2)jCN, -(CH2)jOR3, -(CH2)jC(O)R3, -(CH2)jC(O)OR3, -(CH2)jNR4R5, -(CH2)jC(O)NR4R5, -(CH2)jOC(O)NR4R5, -(CH2)jNR6C(O)R3, -(CH2)jNR6C(O)OR3, -(CH2)jNR6C(O)NR4R5, -(CH2)jS(O)mR7, -(CH2)jNR6S(O)2R7, -(CH2)jS(O)2NR4R5, donde cada j es independientemente un número entero entre 0 y 6, y m es independientemente un número entero entre 0 y 2, o R1 y R2 forman cicloalquilo sustituido o no sustituido, heterocicloalquilo sustituido o no sustituido, arilo sustituido o no sustituido, o heteroarilo sustituido o no sustituido; R3, R4, R5, R6, y R7 son cada uno independientemente hidrógeno, alquilo sustituido o no sustituido, cicloalquilo sustituido o no sustituido, perfluoroalquilo, heteroalquilo sustituido o no sustituido, heterocicloalquilo sustituido o no sustituido, -O-arilo sustituido o no sustituido, arilalquilo sustituido o no sustituido, heteroarilo sustituido o no sustituido, -O-heteroarilo sustituido o no sustituido, o heteroarilalquilo sustituido o no sustituido, o R3, R6 y R7 son según se describe arriba, y R4 y R5, junto con el átomo N al cual están fijados, forman heterocicloalquilo sustituido o no sustituido, o heteroarilo sustituido o no sustituido; R10 es independientemente hidrógeno, arilo sustituido o no sustituido o heteroarilo sustituido o no sustituido, donde R10 es opcional e independientemente sustituido con 1 a 6 R28; ...
CO09040677A 2006-10-23 2009-04-22 Triazoles biciclicos como moduladores de la proteina cinasa CO6190620A2 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US86255206P 2006-10-23 2006-10-23
US87030906P 2006-12-15 2006-12-15
US91376607P 2007-04-24 2007-04-24
US95284007P 2007-07-30 2007-07-30

Publications (1)

Publication Number Publication Date
CO6190620A2 true CO6190620A2 (es) 2010-08-19

Family

ID=38956385

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09040677A CO6190620A2 (es) 2006-10-23 2009-04-22 Triazoles biciclicos como moduladores de la proteina cinasa

Country Status (25)

Country Link
US (1) US8507489B2 (es)
EP (1) EP2084162B1 (es)
JP (1) JP5378222B2 (es)
KR (1) KR20090071612A (es)
AR (1) AR063520A1 (es)
AU (1) AU2007309149C1 (es)
BR (1) BRPI0717320A2 (es)
CA (1) CA2667428A1 (es)
CO (1) CO6190620A2 (es)
CR (1) CR10803A (es)
DK (1) DK2084162T3 (es)
EA (1) EA200970403A1 (es)
ES (1) ES2393130T3 (es)
IL (1) IL197958A0 (es)
MA (1) MA30871B1 (es)
MX (1) MX2009004059A (es)
NO (1) NO20091618L (es)
NZ (1) NZ575336A (es)
PE (1) PE20080893A1 (es)
PL (1) PL2084162T3 (es)
PT (1) PT2084162E (es)
SV (1) SV2009003235A (es)
TN (1) TN2009000142A1 (es)
TW (1) TW200835492A (es)
WO (1) WO2008051808A2 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8792501A1 (es) 2007-08-09 2009-04-23 Sanofi Aventis Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
TWI365185B (en) 2008-07-24 2012-06-01 Lilly Co Eli Amidophenoxyindazoles useful as inhibitors of c-met
UY32049A (es) 2008-08-14 2010-03-26 Takeda Pharmaceutical Inhibidores de cmet
EP2165710A1 (en) 2008-09-19 2010-03-24 Institut Curie Tyrosine kinase receptor Tyro3 as a therapeutic target in the treatment of a bladder tumor
EP2356116A1 (en) 2008-11-20 2011-08-17 OSI Pharmaceuticals, Inc. Substituted pyrroloý2,3-b¨-pyridines and-pyrazines
FR2941952B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-substitue-triazolopyridazine-sulfanyl) 5-fluoro-benzothiazoles et 5-fluoro-benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941950B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-o-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941951B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-nh-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941949B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-o-cycloalkyl ou 6-nh-cycloalkyl- triazolopyridazine-sulfanyl)benzothiazoles et benzimidazoles preparation, application comme medicaments et utilisation comme inhibiteurs de met.
CA2770873A1 (en) 2009-08-12 2011-02-17 Novartis Ag Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
BR112012008061A2 (pt) 2009-08-20 2016-03-01 Novartis Ag compostos de oxima heterocíclica
PE20160588A1 (es) 2009-12-31 2016-07-09 Hutchison Medipharma Ltd Compuestos de triazolopiridinas y triazolopirazinas inhibidores de c-met y composiciones de los mismos
AR081039A1 (es) 2010-05-14 2012-05-30 Osi Pharmaceuticals Llc Inhibidores biciclicos fusionados de quinasa
EP2569315A1 (en) 2010-05-14 2013-03-20 OSI Pharmaceuticals, LLC Fused bicyclic kinase inhibitors
AR085183A1 (es) * 2010-07-30 2013-09-18 Lilly Co Eli Compuesto 6-(1-metil-1h-pirazol-4-il)-3-(2-metil-2h-indazol-5-iltio)-[1,2,4]triazol[4,3-b]piridazina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar cancer
UY33549A (es) * 2010-08-10 2012-01-31 Glaxo Group Ltd Quinolil aminas como agentes inhibidores de las quinasas
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
CN102532141A (zh) 2010-12-08 2012-07-04 中国科学院上海药物研究所 [1，2，4]三唑并[4，3-b][1，2，4]三嗪类化合物、其制备方法和用途
US8765760B2 (en) 2011-01-11 2014-07-01 Sunovion Pharmaceuticals, Inc. [1,2,4] triazol [1,5-a] pyrazines useful as inhibitors of phosphodiesterases
EP2673277A1 (en) 2011-02-10 2013-12-18 Novartis AG [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
CN103459396B (zh) * 2011-02-10 2015-08-19 诺瓦提斯公司 作为c-Met酪氨酸激酶抑制剂的[1,2,4]三唑并[4,3-b]哒嗪化合物
US20140088114A1 (en) 2011-05-16 2014-03-27 OSI Pharmaceuticals ,LLC Fused bicyclic kinase inhibitors
CA2848809A1 (en) 2011-09-15 2013-03-21 Novartis Ag 6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyradines as c-met tyrosine kinase
CN103958509B (zh) * 2011-09-15 2015-12-23 诺华股份有限公司 作为酪氨酸激酶抑制剂的6-取代的3-(喹啉-6-基硫代)-[1,2,4]三唑并[4,3-a]吡啶化合物
AU2013243097A1 (en) 2012-04-03 2014-10-09 Novartis Ag Combination products with tyrosine kinase inhibitors and their use
RU2014143213A (ru) 2012-04-03 2016-05-27 Новартис Аг Соединения ингибитора тирозинкиназы и их применение
CN103122000B (zh) * 2012-09-03 2013-12-25 中美冠科生物技术（太仓）有限公司 用作抗肿瘤药物的高选择性的c-Met激酶抑制剂
WO2014089904A1 (en) * 2012-12-10 2014-06-19 Abbvie Inc. Triazinone compounds
WO2014164195A1 (en) 2013-03-13 2014-10-09 Avon Products, Inc Tyrosinase inhibitors
WO2014164200A1 (en) 2013-03-13 2014-10-09 Avon Products, Inc Tyrosinase inhibitors
KR20180070715A (ko) * 2013-03-13 2018-06-26 에프. 호프만-라 로슈 아게 벤즈옥사제핀 화합물의 제조 방법
US20150152122A1 (en) * 2013-03-13 2015-06-04 Avon Products, Inc. Tyrosinase inhibitors
WO2014174478A1 (en) 2013-04-26 2014-10-30 Novartis Ag Pharmaceutical combinations of a pkc inhibitor and a c-met receptor tyrosine kinase inhibitor
CA2910367C (en) * 2013-05-10 2021-07-20 Jiangsu Hansoh Pharmaceutical Co., Ltd. [1,2,4] triazol [4,3-a] pyridine derivate, preparation method therefor or medical application thereof
CN105272995B (zh) 2015-09-24 2017-10-27 上海海聚生物科技有限公司 喹啉类衍生物、其药物组合物、制备方法及应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604091A (en) 1984-03-01 1997-02-18 Microgenics Corporation Methods for protein binding enzyme complementation
JPS60194443A (ja) * 1984-03-16 1985-10-02 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料
JPS62228086A (ja) * 1985-12-23 1987-10-06 Takeda Chem Ind Ltd セフエム化合物
EP0228061A3 (en) 1985-12-23 1988-12-14 Takeda Chemical Industries, Ltd. Cephem compounds
GB9918035D0 (en) 1999-07-30 1999-09-29 Novartis Ag Organic compounds
WO2002083675A2 (en) 2001-04-10 2002-10-24 Merck Sharp & Dohme Limited Inhibitors of akt activity
WO2002083139A1 (en) 2001-04-10 2002-10-24 Merck & Co., Inc. Inhibitors of akt activity
US20030229453A1 (en) 2002-04-09 2003-12-11 Antonysamy Stephen Suresh Crystals and structures of PAK4KD kinase PAK4KD
RU2005122484A (ru) * 2002-12-18 2006-01-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) Композиции, используемые в качестве ингибиторов протеинкиназ
US7122548B2 (en) * 2003-07-02 2006-10-17 Sugen, Inc. Triazolotriazine compounds and uses thereof
SG156685A1 (en) * 2004-07-27 2009-11-26 Sgx Pharmaceuticals Inc Fused ring heterocycle kinase modulators
PL1784396T3 (pl) 2004-08-26 2011-05-31 Pfizer Związki aminoheteroarylowe podstawione pirazolem jako inhibitory kinazy białkowej
WO2006071548A2 (en) 2004-12-27 2006-07-06 Alcon, Inc. Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases

Also Published As

Publication number Publication date
TW200835492A (en) 2008-09-01
WO2008051808A3 (en) 2008-07-24
TN2009000142A1 (en) 2010-10-18
MX2009004059A (es) 2009-04-27
PE20080893A1 (es) 2008-08-26
PT2084162E (pt) 2012-10-09
NZ575336A (en) 2012-04-27
AR063520A1 (es) 2009-01-28
CR10803A (es) 2009-06-16
NO20091618L (no) 2009-05-22
AU2007309149A1 (en) 2008-05-02
AU2007309149C1 (en) 2013-04-04
EP2084162B1 (en) 2012-09-12
US20090258855A1 (en) 2009-10-15
JP2010507578A (ja) 2010-03-11
PL2084162T3 (pl) 2013-01-31
IL197958A0 (en) 2009-12-24
AU2007309149B2 (en) 2012-09-06
MA30871B1 (fr) 2009-11-02
ES2393130T3 (es) 2012-12-18
DK2084162T3 (da) 2012-10-01
EA200970403A1 (ru) 2009-10-30
JP5378222B2 (ja) 2013-12-25
KR20090071612A (ko) 2009-07-01
SV2009003235A (es) 2009-10-15
CA2667428A1 (en) 2008-05-02
BRPI0717320A2 (pt) 2013-10-22
WO2008051808A2 (en) 2008-05-02
EP2084162A2 (en) 2009-08-05
US8507489B2 (en) 2013-08-13

Similar Documents

Publication Publication Date Title
CO6190620A2 (es) Triazoles biciclicos como moduladores de la proteina cinasa
ES2689037T3 (es) Compuestos y composiciones antihelmínticas y procedimiento de utilización de los mismos
JP2013095751A5 (es)
AR057914A1 (es) Compuestos organicos de azufre y su uso
NO20084742L (no) Aziridinyl-epotilonforbindelser
AR112338A2 (es) Arilciclohexiléteres de dihidro-tetraazabenzoazuleno
CO6241101A2 (es) Derivados de quinolina como inhibidores de la p13 quinasa
AR070437A1 (es) Moduladores de beta - amiloide
AR066210A1 (es) Proceso para producir compuesto amida
CO6150145A2 (es) Derivados de aril/heterociclo/cicloalquil/cicloalquil fenil substituidos utiles como agentes inmunosupresores
SMT201300085B (it) Composti di pirrolo
CY1112914T1 (el) Υποκατεστημενα παραγωγα ινδολυλ αλκυλ αμινης ως νεοι αναστολεις των αποακετυλασων ιστονης
TW200716575A (en) 1,3,5-triazine derivative, method for producing the same, and organic electroluminescent device containing the same as component
AR067356A1 (es) Procesos para la preparacion de pirazoles
RU2007148231A (ru) Способ синтеза органических соединений
MA29399B1 (fr) Nouveaux ligands du recepteur h3 de l'histamine et leurs applications therapeutiques
EA201070246A1 (ru) Циклические аминные соединения
RU2009140295A (ru) Новое конденсированное циклическое ароматическое соединение и содержащее его органическое светоизлучающее устройство
JP2009538336A5 (es)
TW200714674A (en) Near-infrared absorbing material and use thereof
AR067991A1 (es) Pirrolidina-aril-eteres como antagonistas de receptores de nk3
AR074354A1 (es) Alquilciclohexileteres de dihidrotetraazabenzoazulenos, procesos de preparacion y composiciones farmaceuticas que los contienen
ES2421896T3 (es) Compuestos de aril-(imidazol)-metil-fenilo sustituidos como moduladores selectivos de los subtipos de receptores adrenérgicos alfa 2B y/o alfa 2C
JP2016204366A5 (es)
AR050435A1 (es) DERIVADOS DE HIDROXIAMIDA, PROCESOS DE OBTENCIoN Y COMPOSICIONES FARMACÉUTICAS.

Legal Events

Date Code Title Description
FC Application refused